$XBIO
Xenetic Biosciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000168316824005572 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $614.2K $726.4K
YoY Change 0.5% 11.58%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $745.7K $1.130M
YoY Change 0.77% 19.46%
% of Gross Profit
Research & Development $368.0K $933.8K
YoY Change -63.94% 3.38%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.114M $2.064M
YoY Change -36.64% 11.61%
Operating Profit -$499.5K -$1.337M
YoY Change -56.44% 11.62%
Interest Expense $61.30K $63.45K
YoY Change -31.89% -49.68%
% of Operating Profit
Other Income/Expense, Net $62.80K $63.43K
YoY Change -31.09% -56.92%
Pretax Income -$436.7K -$1.274M
YoY Change -58.8% 21.22%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$436.7K -$1.274M
YoY Change -58.63% 21.22%
Net Earnings / Revenue -71.09% -175.38%
Basic Earnings Per Share -$0.28 -$0.83
Diluted Earnings Per Share -$0.28 -$0.83
COMMON SHARES
Basic Shares Outstanding 1.542M shares 1.541M shares
Diluted Shares Outstanding 1.542M shares 1.541M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.840M $7.299M
YoY Change -30.07% -31.95%
Cash & Equivalents $6.840M $7.299M
Short-Term Investments
Other Short-Term Assets $188.1K $716.4K
YoY Change -87.29% -45.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.028M $8.015M
YoY Change -37.57% -33.46%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.018M $1.018M
YoY Change 44.56% 44.56%
Total Long-Term Assets $1.018M $1.018M
YoY Change 44.56% 44.56%
TOTAL ASSETS
Total Short-Term Assets $7.028M $8.015M
Total Long-Term Assets $1.018M $1.018M
Total Assets $8.046M $9.033M
YoY Change -32.73% -29.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $243.3K $283.6K
YoY Change -45.75% 28.16%
Accrued Expenses $766.1K $1.304M
YoY Change 23.56% 100.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.009M $1.588M
YoY Change -5.53% 82.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.009M $1.588M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.009M $1.588M
YoY Change -5.53% 82.21%
SHAREHOLDERS EQUITY
Retained Earnings -$196.1M -$195.7M
YoY Change 2.12% 2.46%
Common Stock $1.545K $1.544K
YoY Change 0.59% 0.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.037M $7.446M
YoY Change
Total Liabilities & Shareholders Equity $8.046M $9.033M
YoY Change -32.73% -29.15%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$436.7K -$1.274M
YoY Change -58.63% 21.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$459.0K -$525.1K
YoY Change -51.68% -58.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -459.0K -525.1K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -459.0K -525.1K
YoY Change -51.68% -58.62%
FREE CASH FLOW
Cash From Operating Activities -$459.0K -$525.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
126103 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
136696 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1540799 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
8677602 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42096 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1273970 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7445728 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
119170 usd
us-gaap Net Income Loss
NetIncomeLoss
-2469083 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7445728 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12859432 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69389 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1050963 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q2 XBIO Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
XBIO Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
CY2024Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
726404 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1237221 usd
CY2023Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
651005 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1256849 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543802 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543385 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1541101 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1540684 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208173105 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208053935 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195703279 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193234196 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7445728 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9033330 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10605226 usd
CY2024Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
726404 usd
CY2023Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
651005 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1237221 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1256849 usd
CY2024Q2 us-gaap Revenues
Revenues
726404 usd
CY2023Q2 us-gaap Revenues
Revenues
651005 usd
us-gaap Revenues
Revenues
1237221 usd
us-gaap Revenues
Revenues
1256849 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
933771 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
903243 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1878092 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1498519 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1130029 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
945950 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1964939 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1871693 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2063800 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1849193 usd
us-gaap Operating Expenses
OperatingExpenses
3843031 usd
us-gaap Operating Expenses
OperatingExpenses
3370212 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1337396 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1198188 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2605810 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2113363 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21122 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25642 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
63447 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
180204 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63426 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
147225 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136727 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
205846 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1273970 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1050963 usd
us-gaap Net Income Loss
NetIncomeLoss
-2469083 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1540799 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1524717 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1524717 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1540741 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1540741 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1520710 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1520710 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138241 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
us-gaap Net Income Loss
NetIncomeLoss
-2469083 usd
us-gaap Net Income Loss
NetIncomeLoss
-1907517 usd
us-gaap Share Based Compensation
ShareBasedCompensation
119170 usd
us-gaap Share Based Compensation
ShareBasedCompensation
138241 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
112553 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
762941 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-362500 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
778017 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-201841 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1684449 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2371558 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1684449 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2371558 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8983046 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7298597 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10725707 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 basis
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
42096 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
69389 usd
us-gaap Share Based Compensation
ShareBasedCompensation
119170 usd
us-gaap Share Based Compensation
ShareBasedCompensation
138241 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40400000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39700000 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005572-index-headers.html Edgar Link pending
0001683168-24-005572-index.html Edgar Link pending
0001683168-24-005572.txt Edgar Link pending
0001683168-24-005572-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20240630.xsd Edgar Link pending
xenetic_ex1001.htm Edgar Link pending
xenetic_ex1002.htm Edgar Link pending
xenetic_ex1003.htm Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-063024.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
xbio-20240630_cal.xml Edgar Link unprocessable
xbio-20240630_def.xml Edgar Link unprocessable
xbio-20240630_lab.xml Edgar Link unprocessable
xbio-20240630_pre.xml Edgar Link unprocessable
xenetic_i10q-063024_htm.xml Edgar Link completed